Alignment Healthcare, Inc. (ALHC) vs Generate Biomedicines, Inc. (GENB)
A side-by-side comparison of Alignment Healthcare, Inc. and Generate Biomedicines, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ALHC
Alignment Healthcare, Inc.
$8.23HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
GENB
Generate Biomedicines, Inc.
$13.69HealthcareDelayed quote: Oct 6, 2026, 10:05 AM EDT
Total return — ALHC vs GENB
growth of $100 · dividends reinvested · last 1yALHC -55.8% (-55.8%/yr)GENB +10.0% (+10.0%/yr)GENB compounded faster over this window
ALHC GENB
ALHC vs GENB: by the numbers
- •GENB is the larger company ($1.75B vs $1.71B market cap).
- •ALHC is profitable (0.89% net margin) while GENB runs a net loss (-636.99%).
Metrics side by side
Valuation
| Metric | ALHC | GENB |
|---|---|---|
| P/E ratio | 44.11 | N/A |
| Forward P/E | 45.33 | N/A |
| P/S ratio | 0.37 | N/A |
| P/B ratio | 6.44 | 3.85 |
| EV / EBITDA | 15.54 | N/A |
Profitability
| Metric | ALHC | GENB |
|---|---|---|
| Gross margin | 12.55% | 100.00% |
| Operating margin | 1.20% | -737.04% |
| Net margin | 0.89% | -636.99% |
| ROE | 15.35% | N/A |
| ROIC | 9.23% | -94.79% |
Growth (annualized)
| Metric | ALHC | GENB |
|---|---|---|
| Revenue CAGR (5Y) | 33.83% | N/A |
| Total return CAGR (5Y) | -12.15% | N/A |
Frequently asked
- Is ALHC or GENB more profitable?
- ALHC runs the higher net margin — ALHC at 0.89% versus GENB at -636.99%.
Go deeper
Dig into the metrics
Alignment Healthcare P/E ratioAlignment Healthcare ROEGenerate Biomedicines ROEAlignment Healthcare operating marginGenerate Biomedicines operating marginAlignment Healthcare revenue growthGenerate Biomedicines revenue growthAlignment Healthcare free cash flowGenerate Biomedicines free cash flow
Alignment Healthcare & Generate Biomedicines appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.